Amgen 2012 Annual Report Download - page 93

Download and view the complete annual report

Please find page 93 of the 2012 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 150

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150

86
Exhibit No. Description
10.40 G-CSF United States License Agreement, dated June 1, 1987 (effective July 1, 1986), Amendment No. 1,
dated October 20, 1988, and Amendment No. 2, dated October 17, 1991 (effective November 13, 1990),
between Kirin-Amgen, Inc. and Amgen Inc. (Filed as exhibits to Form 10-K for the year ended December 31,
2000 on March 7, 2001 and incorporated herein by reference.)
10.41 G-CSF European License Agreement, dated December 30, 1986, between Kirin-Amgen and Amgen,
Amendment No. 1 to Kirin-Amgen, Inc. / Amgen G-CSF European License Agreement, dated June 1, 1987,
Amendment No. 2 to Kirin-Amgen, Inc. / Amgen G-CSF European License Agreement, dated March 15,
1998, Amendment No. 3 to Kirin-Amgen, Inc. / Amgen G-CSF European License Agreement, dated October
20, 1988, and Amendment No. 4 to Kirin-Amgen, Inc. / Amgen G-CSF European License Agreement,
dated December 29, 1989, between Kirin-Amgen, Inc. and Amgen Inc. (Filed as exhibits to Form 10-K
for the year ended December 31, 2000 on March 7, 2001 and incorporated herein by reference.)
10.42 Agreement Regarding Governance and Commercial Matters, dated December 16, 2001, by and among
American Home Products Corporation, American Cyanamid Company and Amgen Inc. (with certain
confidential information deleted therefrom). (Filed as an exhibit to Amendment No. 1 to Form S-4
Registration Statement on March 22, 2002 and incorporated herein by reference.)
10.43 Amended and Restated Promotion Agreement, dated as of December 16, 2001, by and among Immunex
Corporation, American Home Products Corporation and Amgen Inc. (with certain confidential information
deleted therefrom). (Filed as an exhibit to Amendment No. 1 to Form S-4 Registration Statement on March
22, 2002 and incorporated herein by reference.)
10.44 Description of Amendment No. 1 to Amended and Restated Promotion Agreement, effective as of July 8,
2003, among Wyeth, Amgen Inc. and Immunex Corporation (with certain confidential information deleted
therefrom). (Filed as an exhibit to Form 10-K for the year ended December 31, 2003 on March 11, 2004
and incorporated herein by reference.)
10.45 Description of Amendment No. 2 to Amended and Restated Promotion Agreement, effective as of April
20, 2004, by and among Wyeth, Amgen Inc. and Immunex Corporation. (Filed as an exhibit to Amendment
No. 1 to Form S-4 Registration Statement on June 29, 2004 and incorporated herein by reference.)
10.46 Amendment No. 3 to Amended and Restated Promotion Agreement, effective as of January 1, 2005, by
and among Wyeth, Amgen Inc. and Immunex Corporation (with certain confidential information deleted
therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2005 on May 4, 2005 and
incorporated herein by reference.)
10.47 Confirmation of OTC Convertible Note Hedge related to 2013 Notes, dated February 14, 2006, to Amgen
Inc. from Merrill Lynch International related to 0.375% Convertible Senior Notes Due 2013. (Filed as an
exhibit to Form 10-K for the year ended December 31, 2005 on March 10, 2006 and incorporated herein
by reference.)
10.48 Confirmation of OTC Warrant Transaction, dated February 14, 2006, to Amgen Inc. from Merrill Lynch
International for warrants expiring in 2013. (Filed as an exhibit to Form 10-K for the year ended December
31, 2005 on March 10, 2006 and incorporated herein by reference.)
10.49 Credit Agreement, dated as of December 2, 2011, among Amgen Inc., with Citibank, N.A., as administrative
agent, JPMorgan Chase Bank, N.A., as syndication agent, Citigroup Global Markets Inc. and J.P. Morgan
Securities LLC as joint lead arrangers and joint book runners, and the other banks party thereto. (Filed as
an exhibit to Form 8-K filed on December 2, 2011 and incorporated herein by reference.)
10.50 Multi-product License Agreement with Respect to Japan between Amgen Inc. and Takeda Pharmaceutical
Company Limited dated February 1, 2008 (with certain confidential information deleted therefrom). (Filed
as an exhibit to Form 10-Q for the quarter ended March 31, 2008 on May 12, 2008 and incorporated herein
by reference.)
10.51* Amendment No. 1 dated as of June 25, 2010 to the License Agreement dated February 1, 2008 between
Amgen Inc. and Takeda Pharmaceutical Company Limited.
10.52* Amendment No. 2 dated as of June 29, 2012 to the License Agreement dated February 1, 2008 between
Amgen Inc. and Takeda Pharmaceutical Company Limited.